Focus: Renata Medical is a newly founded (2024) medical device company focused on pediatric cardiovascular interventions, specifically stents for infant vascular stenosis. The company operates in the specialized niche of congenital heart disease treatment.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
No open roles listed right now. Follow Renata Medical to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Generic diuretic acquired post-loss of exclusivity; unlikely core to company strategy given pediatric device focus.
Help build intelligence for Renata Medical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Renata Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Generic statin asset in mature market; appears misaligned with stated specialty in pediatric vascular stents.
Generic psychiatric drug with no relevance to cardiovascular device strategy; suggests possible previous business model shift.
Generic triptan with no strategic connection to core pediatric cardiology focus; indicates portfolio misalignment.
Generic beta-blocker in mature market; only vaguely related to cardiovascular space but not device-focused.
No open positions listed yet.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo